Compare MBIN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | TNDM |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | 663 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2017 | 2013 |
| Metric | MBIN | TNDM |
|---|---|---|
| Price | $34.94 | $19.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $39.67 | $24.06 |
| AVG Volume (30 Days) | 136.2K | ★ 1.2M |
| Earning Date | 01-28-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.34 | N/A |
| Revenue | $597,247,000.00 | ★ $1,007,001,000.00 |
| Revenue This Year | $5.17 | $8.59 |
| Revenue Next Year | $7.24 | $10.19 |
| P/E Ratio | $8.13 | ★ N/A |
| Revenue Growth | N/A | ★ 17.87 |
| 52 Week Low | $27.25 | $9.98 |
| 52 Week High | $43.82 | $37.93 |
| Indicator | MBIN | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 35.38 |
| Support Level | $34.51 | $19.61 |
| Resistance Level | $36.82 | $20.60 |
| Average True Range (ATR) | 0.97 | 1.17 |
| MACD | -0.05 | -0.29 |
| Stochastic Oscillator | 28.77 | 0.71 |
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.